OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Duska on Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

August 11th 2025

Linda R. Duska, MD, MPH, discusses the background of the phase 3 KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy in cervical cancer.

Dr Morgans on Enzalutamide Plus Radium-223 in mCRPC

August 11th 2025

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Dr Gershon on Ongoing Research Priorities for NF1-Associated Plexiform Neurofibromas

August 11th 2025

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Dr Ghia on the Rationale for Evaluating Pirtobrutinib in Relapsed/Refractory CLL

August 11th 2025

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

Dr O’Reilly on the Potential of TTFields in Unresectable, Locally Advanced Pancreatic Cancer

August 11th 2025

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Dr Bedke on Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

August 8th 2025

Jens Bedke, MD, discusses findings from subgroup analyses of the phase 3 EV-302/KEYNOTE-A39 trial in untreated metastatic urothelial cancer.

Dr Florez on Emerging Strategies to Address Checkpoint Inhibitor Resistance in NSCLC

August 8th 2025

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Dr Florez on the Role of First-Line IO for BRAF V600E+ Metastatic NSCLC

August 8th 2025

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Dr Kremyanskaya on the Efficacy of Divesiran in Polycythemia Vera

August 8th 2025

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Dr Dietrich on the FDA Approval of Zongertinib for HER2 TKD–Mutated Nonsquamous NSCLC

August 8th 2025

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC

August 8th 2025

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.

Dr Florez on the Role of Chemoimmunotherapy in Borderline Resectable NSCLC

August 8th 2025

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Dr Logan on the Integration of Obe-Cel into Relapsed/Refractory ALL Management

August 7th 2025

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dr Florez on First-Line Treatment Factors in EGFR+ NSCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Dr Florez Highlights Real-Time Polling Results on Treatment Preferences in SCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Dr Malhotra on the Future of Sigvotatug Vedotin in NSCLC

August 7th 2025

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Dr Mehnert on the Rationale for Adding IL-6 Blockade to Checkpoint Inhibition in Melanoma

August 7th 2025

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Dr Eng on the Future Role for Targeted Therapy in mCRC

August 7th 2025

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Dr Cloughesy on the FDA Approval of Dordaviprone for Diffuse Midline Glioma

August 6th 2025

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Dr García-Carbonero on Considerations for Poorly Differentiated GI Neuroendocrine Carcinoma

August 6th 2025

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.